Literature DB >> 6201520

Methotrexate hepatotoxicity.

A J Barak, D J Tuma, H C Beckenhauer.   

Abstract

An inhibitor of folate metabolism, amethopterin (methotrexate) has been successfully used in the treatment of psoriasis and neoplastic disease. This drug produces several dangerous side effects of both an acute and chronic nature which have widely curtailed its use. A serious chronic side effect of the drug is its hepatotoxicity, which may culminate in hepatic cirrhosis and death. To date the underlying mechanism of methotrexate in producing liver damage is unknown. Results of three studies conducted in this laboratory on the nutritional effects of methotrexate offer some evidence that the hepatotoxicity may possibly be incurred through the effect of the drug on methionine biosynthesis and methylation processes. This thesis is discussed in the light of methylating agents vital to the synthesis of methionine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6201520     DOI: 10.1080/07315724.1984.10720041

Source DB:  PubMed          Journal:  J Am Coll Nutr        ISSN: 0731-5724            Impact factor:   3.169


  4 in total

1.  Culture of HepG2 liver cells on three dimensional polystyrene scaffolds enhances cell structure and function during toxicological challenge.

Authors:  Maria Bokhari; Ross J Carnachan; Neil R Cameron; Stefan A Przyborski
Journal:  J Anat       Date:  2007-08-15       Impact factor: 2.610

2.  Methotrexate sensitivity in Down's syndrome: a hypothesis.

Authors:  P M Ueland; H Refsum; B Christensen
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 3.  Hepatotoxicity of methotrexate in rheumatic diseases.

Authors:  S Kevat; M Ahern; P Hall
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun

4.  Effect of methotrexate on homocysteine and other sulfur compounds in tissues of rats fed a normal or a defined, choline-deficient diet.

Authors:  A M Svardal; P M Ueland; R K Berge; A Aarsland; N Aarsaether; P E Lønning; H Refsum
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.